Close Menu

In-Q-Tel

NEW YORK (GenomeWeb News) – Claremont BioSolutions said today it has entered a strategic partnership with investment firm In-Q-Tel to accelerate commercialization of Claremont's Prep-on-a-Chip sample preparation platform.

This article was originally published May 7.

NEW YORK (GenomeWeb News) – OpGen today announced a collaboration with In-Q-Tel to develop a high-throughput sequence and genome mapping pipeline for microbial genome analysis.

Quanterix said this week that it has received an investment of an undisclosed amount from In-Q-Tel, a non-profit investment firm that delivers technology to the US intelligence community.

The undisclosed investment will support the development of a platform for US intelligence applications that will rely on Biomatrica's technology that enables biological samples to be stored at room temperature.

The investment expands Arxcis' ongoing collaboration with IQT to develop Arcxis' fully automated RNA and DNA sample-preparation device, expected to launch later this year.

MBI plans to use the series B venture funding to develop its Apollo sample prep technologies.

Arcxis received an undisclosed investment from In-Q-Tel, which it will use to accelerate development and commercialization of its nucleic acid sample preparation platform and diagnostic consumable product line.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.